Please login to the form below

Not currently logged in
Email:
Password:

Solymbic

This page shows the latest Solymbic news and features for those working in and with pharma, biotech and healthcare.

Amgen wins European approval for Humira biosimilar Amgevita

Amgen wins European approval for Humira biosimilar Amgevita

Meanwhile, in Europe Amgen’s new product has a duplicate marketing authorisation under the brand name Solymbic.

Latest news

  • Merck confirms sale of biosimilar division Merck confirms sale of biosimilar division

    In January, the EMA's Committee for Medicinal Products for Human Use (CHMP) backed approval of the Humira biosimilar under two brand names - Amgevita and Solymbic – with approval expected in the

  • Amgen's Humira biosimilars backed for EU approval Amgen's Humira biosimilars backed for EU approval

    Amgen's Humira biosimilars backed for EU approval. Amgevita and Solymbic prepare to challenge AbbVie’ s blockbuster. ... Amgen's biosimilars - Amgevita (ABP 501) and Solymbic - were recommended for approval by the EMA's scientific advisory panel in

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics